KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Payables (2018 - 2025)

Esperion Therapeutics' Payables history spans 8 years, with the latest figure at $65.1 million for Q4 2025.

  • For Q4 2025, Payables fell 38.75% year-over-year to $65.1 million; the TTM value through Dec 2025 reached $65.1 million, down 38.75%, while the annual FY2025 figure was $65.1 million, 38.75% down from the prior year.
  • Payables reached $65.1 million in Q4 2025 per ESPR's latest filing, down from $132.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $132.4 million in Q3 2025 to a low of $12.8 million in Q2 2022.
  • Average Payables over 5 years is $47.5 million, with a median of $28.9 million recorded in 2021.
  • Peak YoY movement for Payables: plummeted 66.22% in 2021, then soared 345.48% in 2025.
  • A 5-year view of Payables shows it stood at $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then surged by 37.66% to $31.7 million in 2023, then surged by 234.9% to $106.2 million in 2024, then crashed by 38.75% to $65.1 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Payables are $65.1 million (Q4 2025), $132.4 million (Q3 2025), and $129.5 million (Q2 2025).